Product Information
INSULIN DEGLUDEC 100 UNIT/ML VIAL is a generic product labeled by Novo Nordisk, priced at $11.3401 per ML under NDC 73070040011. Its NADAC has been published 129 times since Apr 17, 2024.
Strength
100 U/mL
Manufacturer
Novo NordiskNDC
73070040011
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
5/20/2026
Active Ingredients
INSULIN DEGLUDECApproval Type
Biologic (BLA)
FDA Application
BLA203314On Market Since
7/1/2022
Pharmacological Classes
Price Statistics
The NADAC for INSULIN DEGLUDEC 100 UNIT/ML VIAL has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.3401 per ML |
|---|---|
| All-time high | $11.4272 (Sep 11, 2024) |
| All-time low | $11.3401 (May 20, 2026) |
| 52-week high | $11.3728 |
| 52-week low | $11.3401 |
| Median price | $11.3664 |
| Average price | $11.3697 |
| Largest weekly change | -0.3% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin degludec market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INSULIN DEGLUDEC 100 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for INSULIN DEGLUDEC 100 UNIT/ML VIAL, manufactured by Novo Nordisk, is $11.3401 per ML (NDC 73070040011), effective Sep 30, 2026.
How has the price of INSULIN DEGLUDEC 100 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for INSULIN DEGLUDEC 100 UNIT/ML VIAL has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for INSULIN DEGLUDEC 100 UNIT/ML VIAL?
Since Apr 17, 2024, the NADAC for INSULIN DEGLUDEC 100 UNIT/ML VIAL has ranged from a low of $11.3401 (May 20, 2026) to a high of $11.4272 (Sep 11, 2024), with a median of $11.3664 per ML.
Are there cheaper alternatives to INSULIN DEGLUDEC 100 UNIT/ML VIAL?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRESIBA 100 UNIT/ML VIAL, is $9.0243 per ML — about 20% below INSULIN DEGLUDEC 100 UNIT/ML VIAL.
Who manufactures INSULIN DEGLUDEC 100 UNIT/ML VIAL?
INSULIN DEGLUDEC 100 UNIT/ML VIAL (NDC 73070040011) is labeled by Novo Nordisk, and CMS classifies it as a generic product.